Early Dementia Screening

Diagnostics
Peter K PanegyresJennifer Burchell

Abstract

As the population of the world increases, there will be larger numbers of people with dementia and an emerging need for prompt diagnosis and treatment. Early dementia screening is the process by which a patient who might be in the prodromal phases of a dementing illness is determined as having, or not having, the hallmarks of a neurodegenerative condition. The concepts of mild cognitive impairment, or mild neurocognitive disorder, are useful in analyzing the patient in the prodromal phase of a dementing disease; however, the transformation to dementia may be as low as 10% per annum. The search for early dementia requires a comprehensive clinical evaluation, cognitive assessment, determination of functional status, corroborative history and imaging (including MRI, FDG-PET and maybe amyloid PET), cerebrospinal fluid (CSF) examination assaying Aβ1-42, T-τ and P-τ might also be helpful. Primary care physicians are fundamental in the screening process and are vital in initiating specialist investigation and treatment. Early dementia screening is especially important in an age where there is a search for disease modifying therapies, where there is mounting evidence that treatment, if given early, might influence the natural history-h...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 1, 1990·Archives of Neurology·J McGloneD R Evans
Mar 20, 1987·JAMA : the Journal of the American Medical Association·D M Buchner, E B Larson
Jun 1, 1982·The British Journal of Psychiatry : the Journal of Mental Science·C P HughesR L Martin
Sep 1, 1982·The American Journal of Psychiatry·B ReisbergT Crook
Jan 1, 1982·Journal of Psychiatric Research·J A YesavageV O Leirer
Jul 1, 1995·Journal of the American Geriatrics Society·D M OleskeE W Terman
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
May 16, 2000·Journal of the American Geriatrics Society·K RockwoodJ C Morris
Mar 10, 2001·Clinical Pharmacology and Therapeutics·UNKNOWN Biomarkers Definitions Working Group.
May 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Anne S MatherMarion E T McMurdo
Aug 22, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·P Murali DoraiswamyJeffrey Veach
Jul 10, 2003·Brain Injury : [BI]·Paul Bach-y-Rita
Feb 26, 2004·Aging & Mental Health·S Lliffe, J Manthorpe
Apr 16, 2004·Dementia and Geriatric Cognitive Disorders·C RequenaT Ortiz
Jul 14, 2004·Neurology·Mary GanguliSteven T DeKosky
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
May 19, 2006·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·M A Rocca, M Filippi
Jul 14, 2006·Acta Psychiatrica Scandinavica·D I SitzerD V Jeste
Sep 16, 2009·Archives of Neurology·Sarah Tomaszewski FariasCharles DeCarli
Dec 8, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·Arto NordlundAnders Wallin
Dec 17, 2009·Archives of Neurology·Ronald C PetersenClifford R Jack
Sep 9, 2010·Brain : a Journal of Neurology·James E GalvinJohn C Morris
Oct 15, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kurt R BrundenJohn Q Trojanowski
Feb 25, 2011·Current Opinion in Psychiatry·Tiffany F HughesMary Ganguli
Jun 23, 2011·Journal of Alzheimer's Disease : JAD·Lisa M BloudekSean D Sullivan
Jun 8, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Martin FarlowEric R Siemers
Oct 13, 2012·BMJ Open·Emily R AtkinsPeter K Panegyres
Jul 10, 2013·JAMA Neurology·Keith A VosselLennart Mucke
Aug 7, 2013·European Archives of Psychiatry and Clinical Neuroscience·Jing Ming YeoSuvankar Pal
Oct 3, 2013·The British Journal of Psychiatry : the Journal of Mental Science·Claudia CooperGill Livingston
Oct 8, 2013·Clinics in Geriatric Medicine·J Riley McCarten
Oct 15, 2013·International Journal of Geriatric Psychiatry·Christopher M Davison, John T O'Brien
Oct 18, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Lorna HarperNick C Fox
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group

❮ Previous
Next ❯

Citations

May 6, 2016·Aging & Mental Health·Susan Devoy, Ellen Elizabeth Anne Simpson
Dec 13, 2016·Neurología : publicación oficial de la Sociedad Española de Neurología·T Vega AlonsoM Fragua Gil
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Lucy C BeishonVictoria J Haunton
Dec 13, 2019·Journal of Medical Systems·Fadi ThabtahJithin Varghese
Jan 31, 2020·Acta Clinica Belgica·De Lepeleire JanSchoenmakers Birgitte
May 15, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Anand VenkatramanPankaj Arora
May 10, 2020·International Journal of Geriatric Psychiatry·Yoko Aihara, Kiyoshi Maeda
Jun 28, 2018·Aging Clinical and Experimental Research·Alessandro IavaroneUNKNOWN Working Group
Sep 28, 2017·American Journal of Alzheimer's Disease and Other Dementias·Arsalan DamirchiParvin Babaei
Sep 9, 2016·Anaesthesia and Intensive Care·M H M ChuM Chan
Oct 22, 2020·The Journal of International Medical Research·Maria Cristina De ColaViviana Lo Buono
Dec 23, 2020·International Journal of Environmental Research and Public Health·Sunghee KimKyoungsook Lee
Aug 16, 2021·Cost Effectiveness and Resource Allocation : C/E·Young-Sil LeeKi Woong Kim
Nov 4, 2021·International Journal of Aging & Human Development·Xi PanNicholas Joseph Bishop
Sep 23, 2020·Journal of Biomedical Informatics·Fadi ThabtahChanchala Hathurusingha
Jul 7, 2021·European Geriatric Medicine·Stephen C CunnaneAlfonso J Cruz-Jentoft

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Journal of Alzheimer's Disease : JAD
Joshua A SonnenThomas J Montine
Missouri Medicine
Suzanne E SchindlerMarc I Diamond
Proceedings of the Annual Meeting of the American Psychopathological Association
D Cohen, D Dunner
© 2021 Meta ULC. All rights reserved